Genetic Testing And Results In Population-Based Breast Cancer Patients And Ovarian Cancer Patients

1578Background: Genetic testing for cancer risk has expanded rapidly, with more genes tested. Little is known about test use or pathogenic variant (PV) prevalence among population-based cancer patients. Methods: Women aged ≥20 years, diagnosed with breast or ovarian cancer in 2013-14 and reported to SEER registries covering the entire populations of Georgia and California, were included. Registry data were linked to clinical genetic testing results, performed from 1/1/2012 through 4/30/2016, by 4 laboratories that did nearly all cancer genetic testing in these states. Results: There were 77,085 breast cancer and 6,001 ovarian cancer patients, with almost 30,000 patients of racial groups other than non-Hispanic (NH) White. One-quarter (24.1%) of breast and one-third (30.9%) of ovarian cancer patients had genetic test results. While test use was similar across racial groups for breast cancer, testing in ovarian cancer patients was lower in NH Blacks (21.6%, CI 18.2-25.4%, vs NH Whites: 33.8%, CI 32.3-35.4%)...